Abstract:
This document describes materials and methods for, for example, producing 6-hydroxyhexanoic acid using a β-ketothiolase or synthase and an alcohol O-acetyltransferase to form a 6-acetyloxy-3-oxohexanoyl-CoA intermediate. This document describes biochemical pathways for producing 6-hydroxyhexanoic acid using a β-ketothiolase or synthase and an alcohol O-acetyltransferase to form a 6-acetyloxy-3-oxohexanoyl-CoA intermediate. 6-hydroxyhexanoic acid can be enzymatically converted to adipic acid, caprolactam, 6-aminohexanoic acid, hexamethylenediamine or 1,6-hexanediol. This document also describes recombinant hosts producing 6-hydroxyhexanoic acid as well as adipic acid, caprolactam, 6-aminohexanoic acid, hexamethylenediamine and 1,6-hexanediol.
Abstract:
The present invention relates to a method for preparing a recombinant microorganism simultaneously comprising genes encoding enzymes used for a biosynthesis pathway of 6-aminocaproic acid which is a precursor of caprolactam, biosynthesizing 6-aminocaproic acid from the microorganism, and producing same so as to synthesize caprolactam.
Abstract:
The present invention relates to an improved method for the fermentative production of gamma-aminobutyric acid (GABA) by cultivating a recombinant microorganism expressing an enzyme having a glutamate decarboxylase activity, wherein the recombinant microorganism has an amended expression of certain enzymes influencing the GABA production and / yield. The present invention also relates to corresponding recombinant hosts, recombinant vectors, expression cassettes and nucleic acids suitable for preparing such hosts as well as to a method for preparing pyrrolidone and polymers making use of GABA as obtained by fermentative production.
Abstract:
Provided herein are methods, compositions, and non-naturally occurring microbial organism for preparing compounds such as1-butanol, butyric acid, succinic acid, 1,4-butanediol, 1-pentanol, pentanoic acid, glutaric acid, 1,5-pentanediol, 1-hexanol, hexanoic acid, adipic acid, 1,6-hexanediol, 6-hydroxy hexanoic acid, ε-Caprolactone, 6-amino-hexanoic acid, ε-Caprolactam, hexamethylenediamine, linear fatty acids and linear fatty alcohols that are between 7-25 carbons long, linear alkanes and linear -alkenes that are between 6-24 carbons long, sebacic acid and dodecanedioic acid comprising: a) converting a CN aldehyde and pyruvate to a CN+3 -hydroxyketone intermediate through an aldol addition; and b) converting the CN+3 -hydroxyketone intermediate to the compounds through enzymatic steps, or a combination of enzymatic and chemical steps.
Abstract:
Die Erfindung betrifft ein Verfahren zur fermentativen Herstellung von γ-Glutamylcystein und dessen Derivaten bis-γ-Glutamylcystin und γ-Glutamylcystin bei dem ein zur γ-Glutamylcystein-Produktion geeigneter prokaryotischer Mikroorganismenstamm in einem Fermentationsmediums kultiviert wird, dadurch gekennzeichnet, dass das Fermentationsmedium zu Beginn der γ-Glutamylcystein-Produktionsphase auf einen pH-Wert größer 5,0 und kleiner 6,5 eingestellt wird.
Abstract:
본 발명은 L-글루타민산 나트륨(Monosodium L-glutamate, MSG) 분해능을 갖는 신규한 락토바실러스 브레비스( Lactobacillus brevis ) G-101 균주 및 이를 유효성분으로 포함하는 건강기능식품, 약학적 조성물, 또는 식품에 관한 것으로, 보다 구체적으로 상기 균주는 동물 체내의 혈중 MSG를 감소시키고 MSG 복합 증후군을 감약하는 효과가 있는바, 유해한 것으로 알려진 MSG의 체내 흡수 억제 내지 MSG 복합 증후군 개선 등을 목적으로 한 건강기능식품, 약학적 조성물 또는 식품으로 이용될 수 있다.
Abstract:
The present invention relates to an RhtB (homoserine/homoserine lactone export transporter) protein variant having an enhanced ability to export O-phosphoserine (OPS) that is a precursor of L-cysteine, a polynucleotide encoding the protein, a vector comprising the polynucleotide, an OPS-producing microorganism comprising the protein variant, a method of producing O-phosphoserine using the microorganism, and a method for preparing cysteine or its derivatives, which comprises reacting O-phosphoserine, produced by the method above, with a sulfide in the presence of O-phosphoserine sulfhydrylase (OPSS) or a microorganism that expresses OPSS.
Abstract:
This document describes biochemical pathways for producing pimelic acid, 7-aminoheptanoic acid, 7-hydroxyheptanoic acid, heptamethylenediamine or 1,7-heptanediol by forming one or two terminal functional groups, each comprised of carboxyl, amine or hydroxyl group, in a C7 aliphatic backbone substrate. These pathways, metabolic engineering and cultivation strategies described herein rely on the C1 elongation enzymes or homolog associated with coenzyme B biosynthesis.
Abstract:
This document describes biochemical pathways for producing adipic acid, caprolactam, 6-aminohexanoic acid, 6-hydroxyhexanoic acid, hexamethylenediamine or 1,6-hexanediol by forming two terminal functional groups, comprised of carboxyl, amine or hydroxyl groups, in a C6 aliphatic backbone substrate. These pathways, metabolic engineering and cultivation strategies described herein rely on CoA-dependent elongation enzymes or analogues enzymes associated with the carbon storage pathways from polyhydroxyalkanoate accumulating bacteria.
Abstract:
This document describes biochemical pathways for producing pimelic acid, 7-aminoheptanoic acid, 7-hydroxyheptanoic acid, heptamethylenediamine or 1,7-heptanediol by forming two terminal functional groups, comprised of carboxyl, amine or hydroxyl group, in a C7 aliphatic backbone substrate. These pathways, metabolic engineering and cultivation strategies described herein rely on enzymes or homologs accepting methyl ester shielded dicarboxylic acid substrates.